ILARIS (canakinumab), interleukin 1 inhibitor

• ILARIS has Marketing Authorisation in the treatment of three forms of hereditary recurrent fevers in adults, adolescents and children aged 2 years and older:
•  TNF-associated periodic syndrome (TRAPS),
•  hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and
•  familial Mediterranean fever (FMF).
• Its superiority relative to placebo has been demonstrated in these 3 diseases in terms of resolution of the initial attack at 15 days and absence of new flare-up within 4 months after treatment. 
• ILARIS has not shown to have a long-term effect in the prevention of secondary amyloidosis, a source of morbidity and mortality.

-